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Abstract Endothelin-1 (ET-1) is an endothelium-derived
peptide that also possesses potent mitogenic activity. There
is also a suggestion the ET-1 is a neuropeptide, based
mainly on its histological identification in both the central
and peripheral nervous system in a number of species,
including man. A neuropeptide role for ET-1 is supported
by studies showing a variety of effects caused following its
administration into different regions of the brain and by
application to peripheral nerves. In addition there are
studies proposing that ET-1 is implicated in a number of
neural circuits where its transmitter affects range from a
role in pain and temperature control to its action on the
hypothalamo-neurosecretory system. While the effect of
ET-1 on nerve tissue is beyond doubt, its action on nerve
blood flow is often ignored. Here, we review data generated
in a number of species and using a variety of experimental
models. Studies range from those showing the distribution
of ET-1 and its receptors in nerve tissue to those describing
numerous neurally-mediated effects of ET-1.
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Abbreviations
2DG 2-deoxyglucose
ANS autonomic nervous system
Ax axon
At axon terminal
Av agranular vesicles
BVS blood vessels
CSF cerebrospinal fluid
CGRP calcitonin gene-related peptide
CNS central nervous system
Ds dendrite spine
ECE endothelin converting enzyme
[
125I]-ET-1 iodinated endothelin-1
ET-1 endothelin-1
ET-2 endothelin-2
ET-3 endothelin-3
ETA endothelin A receptor
ETB endothelin B receptor
GABA γ-amino butyric acid
Gv granular vesicles
ICV intracerebroventricular
Idcn intermediate dorsal cutaneous nerve
Lm lateral malleolus
LPS lipopolysaccharide
M mitochondrium
mRNA Messenger ribonucleic acid
NA noradrenaline
NO nitric oxide
Concise summary Apart from its vascular effects it has been
suggested that endothelin-1 (ET-1) is a neuropeptide. This is based on
the histological identification of ET-1 in nervous tissue with supporting
data from functional studies. Here we review a number of studies into
the potential neurotransmitter role of ET-1 and discuss its
confounding neurovascular effects.
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SAH subarachnoid hemorrhage
SCG superior cervical ganglion
Sch Schwann cell
TG trigeminal ganglion
TH tyrosine hydroxylase
V vacuoles
Introduction
Apart from its well-established vascular effects a number of
studies suggest that endothelin-1 (ET-1) possesses neuro-
peptide properties via both ETA and ETB receptor subtypes.
Perhaps one of the first publications in support of this
proposition was the identification of positive immunostain-
ing for ET-1 in neurones of the human spinal cord (Giaid et
al. 1989). Furthermore, ultrastructural studies provided
supporting evidence for a neurotransmitter role for ET-1 since
ET-1-containing vesicles were identified in perivascular
nerves of the rat basilar artery (Loesch et al. 1998).
Centrally-mediated actions of ET-1 were described within a
few years of its identification based on blood pressure effects
elicited in rats following intracerebroventricular administra-
tion (Macrae et al. 1991a, 1993). A neurotransmitter role for
ET-1 has also been proposed in the peripheral nervous
system as topical application of this peptide was shown to
alter nerve conduction (Zochodne et al. 1992). Since
publication of these early studies there may be some doubt
regarding the transmitter properties of ET-1 as many reports
over the last two decades suggest rather than being a
neurotransmitter the actions of ET-1 are neurovascular. In
this review, of the three endothelin isoforms (ET-1, ET-2 and
ET-3) we focus mainly on ET-1 and discuss early histolog-
ical data providing evidence that this peptide acts on sites
within the central (CNS), autonomic (ANS) and peripheral
(PNS) nervous systems and studies showing the consequen-
ces of application of ET-1 to these sites. Later reports
describe neurovascular effects of ET-1 suggesting that many
‘neural’ actions attributed to this peptide may be secondary
to reduced blood flow and ischaemia of nerve tissue.
Distribution of ET-1
Following the isolation and identification of ET-1 and the
description of its vascular effects (Yanagisawa et al. 1988)i t
was not long before this vascular endothelium-derived factor
was suggested to possess neuropeptide properties. Much of
this was based on the initial immunohistochemical identifi-
cation of ET-1 in nerve tissue from a number of species,
including rat, mouse and human (Shinmi et al. 1989;
Yoshizawa et al. 1990; Lee et al. 1990; Giaid et al. 1991;
Franco-Cereceda et al. 1991;N a k a m u r ae ta l .1993;
Gajkowska and Viron 1996). Regarding a potential neuro-
peptide role for ET-1 in vascular control, ET-1-positive
varicosities have been identified in perivascular nerves of
the basilar artery of the rat (Loesch et al. 1998) and capybara
(Loesch et al. 2005) with a similar distribution in perivas-
cular nerves/axons in human middle cerebral artery (Loesch
et al. 2004, Loesch and Burnstock 2002; Mickey et al.
2002). In the periphery ET-1 has been shown to participate
in pain-related processes (Khodorova et al. 2003, 2009).
ET-1 and the CNS
Distribution of ET-1 in the CNS
Apart from describing ET-1 distribution in brain of various
experimental animals this peptide has also been identified
in human brain (Naidoo et al. 2004a, b). In addition, ET-1
mRNA and ET-1-like immunoreactivity has been described
in human spinal cord and dorsal root ganglia with the
authors concluding that ET-1 plays a part in neural
transmission/modulation in addition to its vascular actions
(Giaid et al. 1991).
Neurotransmitter actions of ET-1 in the CNS
The effects of drugs acting on the CNS may be studied in
animals by administration into the cerebral ventricles. This
technique was introduced over 50 years ago (Feldberg and
Sherwood 1954) and, using such an approach, centrally-
mediated effects of many drugs have been described. For
example, the potential central inhibitory effect of endogenous
opioid peptides on the adrenal medulla, have been suggested
based on intracerebrovascular (ICV) administration of the
opiate receptor antagonist, naloxone, in the cat (Dashwood
and Feldberg 1979). In particular, ICV injection in rats,
mostly into the lateral ventricles, is commonly used for
screening of compounds with potential central cardiovascular
activity. Here, the tip of the cannula is placed into the ‘liquor
spaces’, often under asceptic conditions, using stereotaxic
guidance. Drugs administered by this route bypass the blood
brain barrier, a structure that prevents many compounds
reaching the brain when given systemically. Once injected
into the cerebroventricular system compounds combine with
the cerebrospinal fluid where they are able to act on many
superficial brain structures. For example, the potential effects
of a variety of neurotransmitters have been studied following
52 M.R. Dashwood, A. Loeschadministration into the aqueduct, lateral and third ventricles,
routes that target various superficial structures ‘adjacent’ to
this compartment, including the periaqueductal gray matter
and the hypothalamus (See Fig. 1).
ET-1 in the CNS: neuropeptide or cerebrovascular effects?
Patterns of brain activity may be studied by measuring local
cerebral energy metabolism using 2-deoxyglucose (2DG)
where altered uptake is suggested to be related to the local
energy demands of nerve cells and therefore of nerve activity
(Sokoloff 1978, 1984). This technique has been used to
study neural ‘activity’ in many situations, particularly in
relation to central cardiovascular control (Kostreva 1983).
More recently the role of the cerebral microvasculature in
supplying oxygen to ‘active’ nerve cells has been discussed
with the proposal that 2DG reflects changes in blood flow
rather than neural activity (Shepherd 2003). Although there
is general acceptance that drugs acting when injected into the
cerebral ventricles may affect neurotransmission it is clear
that this may not necessarily be due to their neurotransmitter
properties, more their action on the blood supply to various
regions of the brain (Shepherd 2003). This suggestion was
explored where the effect of ET-1 on cerebral blood flow
was investigated following ICVadministration. Experimental
evidence was provided that ICVadministration of ET-1 alters
blood flow in the rat brainstem (Macrae et al. 1991b)w i t h
further data showing that this also occurs in vivo in cat
cerebral resistance arterioles (Patel et al. 1996). Interestingly,
where adventitial application of ET-1 and endothelin receptor
antagonists was performed, ETA receptors were shown to be
involved in constriction and ETB receptors with dilatation
(Patel et al. 1996). These results are potentially important
since in the peripheral vasculature ETB-receptor activation
may also elicit vasoconstriction. If a similar distribution of
vascular receptors occurs in man, selective ETA antagonist
treatment may have therapeutic potential in certain cerebro-
vascular diseases. This suggestion is supported by a study
using the mixed antagonist, bosentan, in the rat middle
cerebral artery occlusion model. Here, the effects of bosentan
on cortical perfusion was investigated using laser Doppler
flowmetry where this compound failed to reveal a significant
contribution of endogenous ET-1 in this model of focal
ischaemic injury. The authors conclude that selective (not
‘mixed’) antagonists were needed to target ET-1-induced
ischemia (McAuley et al. 1996).
A similar series of studies have been reported where ICV
administration (into the lateral ventricle) of ET-1 in the rat
was investigated. Initially, this group studied the potential
central effect of ET-1 on systemic haemodynamics and
regional blood flow using a radioactive microsphere
technique. Whereas low doses (5 and 15 ng) of ICV ET-1
were ineffective, high doses (>45 ng) were shown to cause
a transient rise, followed by a fall, in systemic blood
pressure. These effects were accompanied by reduced blood
flow to the brain, heart, kidneys, gastrointestinal tract,
portal and musculo-skeletal systems. Pharmacological
extension of these studies showed that these effects were
mediated solely via ETA receptors (Rebello et al. 1995). Ina
subsequent study this group extended their findings by
comparing the effects of ICV administration of ET-1 and
ETA/ETB receptor-selective compounds. In addition to using
Fig. 1 Representative frontal sections of rat brain. Frontal sections of
rat brain (Sudan black staining) at three different levels from rostral
a to caudal c showing: in a the lateral ventricles (arrow), in b third
ventricle (arrow) and thalamus-hypothalamus with supraoptic nucleus
(asterisk), and in c showing aqueduct (arrow) and periaquedutcal gray
area (asterisk). ET-1 adiministration to such regions has cardiovascu-
lar (D’Amico et al. 1996; McAuley et al. 1996; Macrae et al. 1991a, b;
Macrae et al. 1993) and temperature-regulating effects (Fabricio et al.
2005)
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Here the authors showed that many of the effects of centrally
administeredET-1,suchasthefallinsystemicbloodpressure,
were accompanied by a significant decrease in sympathetic
nerve activity and that these effects were mediated via ETA
receptors (Gulati et al. 1997; Kumar et al. 1997).
Macrae et al. (1991b) have shown that intracisternal
administration of ET-1 in the normotensive rat caused a
widespreadandprofoundischaemiaofthecaudalbrainstem,a
region involved in central cardiovascular control. ICV ET-1
injection produced a rise in mean arterial blood pressure and
concomitantelevationofplasmanoradrenaline andadrenaline
levels. The authors conclude that ET-1 has the potential to
induce cerebral ischaemia of pathological magnitude and
wisely suggest that caution is needed when drawing con-
clusionsfromICV drugadministrationasET-1isalsocapable
of overriding cerebrovascular autoregulatory mechanisms.
The potential for ICV administered compounds to affect
the cerebral circulation is evident from recent angiographic
data produced in rats exhibiting drowsiness and coma
caused by brain tumor (Hekmatpanah 2007). Here, a dense
vascular network in normal rats was revealed using barium
sulphate contrast medium (see Fig. 2). In control animals,
magnified angiograms revealed perforating microvessels
that penetrate the brain and, while their diameter is too
small to be detected by routine cerebral angiography, India
ink injections revealed small/terminal capillaries throughout
the brain (Fig. 2). Interestingly, the author (Hekmatpanah
2007) describes infarcted and ischaemic changes to micro-
vessels of rats with brain tumours similar to those that
might be expected following administration of vasocon-
strictors such as ET-1.
Further evidence for a predominant involvement of the
ETA receptor in the central cardiovascular effect of ET-1
was suggested where central administration of ET-1 was
performed after stereotaxic placement of a needle tip into
the periaqueductal gray area (D’Amico et al. 1996). These
injections elicited a dose-dependent increase in mean
arterial pressure but a fall in renal blood flow. Pretreatment
with ETA-selective antagonists reduced these effects but
ETB receptor blockade was ineffective. The potential role
of ETA receptors was supported by in vitro autoradiograph-
ic studies that showed dense [
125I]-PD 151242 binding to
many brain regions of the rat brain (including the
periaqueductal gray area) and a paucity of ETB-receptor
binding sites (D’Amico et al. 1996). Again, the existence of
the dense microvascular network in many brain regions,
including the PAG, requires a potential vascular involvement
of central ET-1 application to be considered (See Fig. 3).
A practical point that is ignored in many studies is the
potential spread of what are believed ‘discrete’ injections
and ‘drug targeting’. An injection volume of 1 µl will
occupy an approximate area of 1 mm
3. Such an area may
encompass many brain nuclei that are likely to contain a
dense network of cerebral vessels (Figs. 2 and 3).
In such a scenario caution is recommended if a
neuropeptide action is suggested based on the effect(s) of
centrally administered compounds.
Supporting evidence for a transmitter role for ET-1 has
been described recently by Nabhen et al. (2009) where the
co-existence of ET-1 and catecholaminergic neurones
suggests that ET-1 may be a neuromodulator. Olfactory
bulbs were obtained from normal rats and incubated in the
presence/absence of ET-1, ET-3 and ET receptor antagonists.
Fig. 2 Cerebral vessels. Left
panel. Magnification angiogra-
phy of normal rat brain using
barium sulphate contrast medi-
um. There is an abundant vas-
cular supply with many
penetrating microvessels in the
cortex shown in the right panel
following intra-arterial injection
of India ink (black regions of a
haemotoxylin and eosin stains
section). Scale bar=5 mm for
the left panel and 50 µm for the
right panel. Modified from
Hekmatpanah Surg Neurol
2007;67:564-71
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blots performed and neuronal norepinephrine release mea-
sured. In the short term ET-1 and ET-3 both increase TH
activity in vitro and this involved various mechanisms
including increased calcium influx. This is said to be the
first report showing an interaction between ET-1 and
catecholaminergic transmission in olfactory bulbs and future
studies are recommended to evaluate the relationship with
the various other functions at this level of the brain.
CNS: ET-1 and the hypothalamo-neurosecretory system
While the endothelins and ET receptors have been detected
in a number of structures throughout the CNS (Arai et al.
1990; Lee et al. 1990; Yoshizawa et al. 1990; Hemsen and
Lundberg 1991; Nakamura et al. 1993; Horowitz et al.
1994; Uemura et al. 1994; Kurokawa et al. 1997; Yamada
and Kurokawa 1998; Kurokawa et al. 2000), similar
observations have been described in the endocrine
hypothalamo-neurohypophysial secretory system that is
responsible for delivering vasopressin and oxytocin to
blood from neurosecretory axon terminals in the neurohy-
pophysis (Krsmanović et al. 1991; Cao et al. 1993;
Nakamura et al. 1993; Yasin et al. 1994; Mosqueda-
Garcia et al. 1995; Kurokawa et al. 1997). Here we present
selected examples of research relevant to the subject. A
double immunogold co-labelling study by Nakamura et al.
(1993) showed the colocalisation of immunoreactive ET-1
and vasopressin as well as ET-1 and oxytocin in sub-
populations of neurohypophysial axons of the rat. Also, co-
expression of genes for ET-1 and oxytocin has been
revealed in the rat during pregnancy (Horowitz et al.
1994); ET-1 mRNA has been shown to be increased
significantly in the supraoptic and paraventricular nuclei
from early to late gestation as has oxytocin gene expression
as gestation advanced. Consequently, a neuroendocrine
regulatory role for ET-1 in pregnancy has been suggested
(Horowitz et al. 1994). A study of ET-1 gene transcription
in rat supraoptic nucleus following injury showed the
dynamism of ET-1-related mechanisms, namely time-
associated changes in the expression of ET-1 mRNA and
immunoreactivity to ET-1, suggesting an important role for
ET-1 in neuroendocrine events following injury (Jiang et al.
2000).
Our own studies showed immunoreactive ET-1 within
the rat hypothalamo-neurosecretory system, where ET-1
was detected in the cell bodies of endocrine neurons and
in their processes containing neurosecretory granules
(Mukherjee and Loesch 2002) (Fig. 4a). ET-1 was also
detected in the axon terminals making axo-dendritic syn-
apses; such terminals contain typical synaptic vesicles –
mostly small agranular vesicles (Fig. 4b). Furthermore, these
studies revealed a proportion of ET-1-positive endocrine
neurons and their processes, as well as ET-1-positive axon
terminals making axo-dendritic synapses that were also
immunoreactive for neuronal nitric oxide synthase (nNOS).
(Fig. 4a, b).
The significance of nNOS/ET-1 colocalisation may be
difficult to explain but suggests that cotransmission and/or
neuromodulation by ET-1 and NO occurs within these
nerves. In general this supports the putative roles of NO
and ET-1 in the CNS and PNS (Giaid et al. 1989; Snyder
and Bredt 1992; Garthwaite and Boulton 1995; Knuepfer et
al. 1994; Hoyle and Burnstock 1995; Lincoln et al. 1997;
Rubino et al. 1999). Similarly, physiological roles for NO/
nNOS and endothelins in hypothalamo-neurohypophysial
neurosecretion may also occur (Yoshizawa et al. 1990;
Yasin et al. 1993; Reid 1994; Rettori et al. 1997; Ng et al.
1999; Wang & Morris 1999; Costa et al. 2000; Kurokawa
Fig. 3 ET-1 action on the periaqueductal gray area of the rat. Top
panel. ETA receptors ([
125I-PD 151252 binding) in the rat brain
identified by in vitro autoradiography (from D’Amico et al. 1996).
Periaqueductal gray area (PAG) is outlined. Lower panel. Cerebral
vessels of the PAG identified by immunohistochemistry (arrows
indicate CD31 staining of vessel endothelium, red). (Dashwood
unpublished) *indicates the aqueduct. Scale bars=2.5 mm for the
top and 50 µm for the lower panels
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input at the level of the hypothalamic neurosecretory cell
bodies of supraoptic and paraventricular nuclei is character-
ised by the presence of noradrenaline (NA), γ-aminobutyric
acid (GABA) and glutamate (see Buller et al. 1996;S p e r r l á g h
et al. 1998; Theodosis et al. 1998). Therefore it is likely that
some of these axonal neurochemical inputs also include ET-1
and nNOS. Studies using hypothalamic explants from rat
showed that NO inhibits the release of vasopressin (Yasin et
al. 1993), while oxytocin may stimulate the release of NO
from oxytocinergic neurones via NA-related mechanisms
(Rettori et al. 1997). In rat, ET-1 converting enzyme (ECE;
that converts its precursor big ET-1 to mature ET-1) is present
in a subpopulation of neurosecretory neurons, including
their axons, of the hypothalamo-neurohypophysial tract
(Kurokawa et al. 2000). Histochemical evidence suggests
that big ET-1 is secreted as a neurohormone from nerve
terminals into the neurohypophysial blood vessels (Yamada
and Kurokawa 1998). Hypothalamic endocrine nuclei display
ET binding, in particular to ETA receptors (Kurokawa et al.
1997; Yamada and Kurokawa 1998). Strikingly, increases in
circulating levels of ET-1 affect the hypothalamic endocrine
nuclei producing predominantly excitatory effects on
vasopressin- and oxytocin-neurones (Wall & Ferguson
1992). A recent study of the rat hypothalamus showed
that ET-1 decreases neuronal NA uptake in the anterior
hypothalamus and diminishes the uptake in the posterior
hypothalamic region (Hope et al. 2008).
In addition to its neuroendocrine involvement the
hypothalamus plays an important role in thermoregulation
(Feldberg 1965). The potential role of ET-1 as a central
mediator of fever has been studied where levels of big ET-
1, the precursor of ET-1, were measured in cerebral spinal
fluid (CSF) from rats after intravenous administration of
lipopolysaccharide (LPS). Interestingly, big ET-1 levels in
cisternal CSF fell in febrile rats versus controls, but levels
were significantly increased in rats that had received ICV
administration of the ETB antagonist, BQ788. Furthermore,
intrahypothalamic injection of ET-1 caused a substantial
and long lasting rise in rectal temperature. The authors
conclude that LPS-induced fever in rat enhances ET-1
production in the brain (via measurement of big ET-1) and
that ET-1 is an endogenous pyrogen (Fabricio et al. 2005).
ET-1 and the PNS/ANS
Cerebrovascular autonomic nerves
Although the endothelium is recognized as a major source
of ET-1 in the vasculature it was reported that the
autonomic perivascular nerves in rat basilar artery are
immunopositive for ET-1 with 36% of the axon profiles
(varicosities and intervaricosities) in the adventitia of the rat
basilar artery observed at the electron microscopic level
being immunolabelled for ET-1 (Loesch et al. 1998). Axon
Fig. 4 Neuropil of supraoptic nucleus of the hypothalamus double-
labelled for nNOS (immunoprecipitate - long arrows) and ET-1
(immunogold-silver grains – short arrows). a A fragment of a double-
labelled dendrite (likely to be a primary or varicose dendrite from a
bipolar magnocellular neurone) shows abundance of neurosecretory
granules (nsg), of which some are nNOS-positive (long arrows); short
arrows point to immunoreactivity for ET-1. Note unlabelled axon profile
(Ax) making synapse on the double-labelled dendrite. b A double-
labelled axon terminal (At) making asymmetric synapse with unlabelled
dendrite spine (ds). The axon terminal contains numerous small
agranular synaptic vesicles, membrane of which is labelled with nNOS
immunoprecipitate; co-localised immunogold-silver grains of ET-1
labelling (arrows) are also seen. Note that an adjacent axon profile
(Ax) containing small agranular synaptic vesicles is unlabelled; m-
mitochondria. Bars: 0.5 μm. Affinity-purified rabbit polyclonal nNOS
antibody (SC-1025, Santa Cruz, USA), which does not cross react with
NOS2 and NOS3 was used at 0.8μg/ml in the preembedding ExtrAvidin
immunocytochemical method. The rabbit polyclonal ET-1 antibody to
human/porcine ET-1 (Sigma, Poole, UK), which does not cross-react
with big ET but may with ET-2 and ET-3 was used at 1:1,000 in the
preembedding immunogold-silver labelling method as the second
immunolabelling. Images A and B are modified from Mukherjee and
Loesch, Histochem J 2002, 34:181-187 [Kluwer Academic Publishers],
which is kindly acknowledged
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small agranular vesicles (~ 42 nm) and large granular
vesicles (~92 nm) with ET-1-labelled cores (Fig. 5a).
Subsequent studies focusing on the basilar artery of
spontaneously hypertensive rats showed an increase in ET-
1-positive perivascular axons in such conditions, although
these axons usually displayed structural abnormalities
(Fig. 5b) (Milner et al. 2000a). Combined immunohisto-
chemical, in situ hybridisation and sensory and sympathetic
denervation studies revealed that the ET-1-containing
cerebrovascular nerves originate from the sensory and
sympathetic components of the trigeminal (TG) and superior
cervical (SCG) ganglia and that the ET-1 in a proportion of
the TG neurons is co-localised with sensory substance P
(Milner et al. 2000a, b). This suggests that the sensory
TG is the more likely source of ET-1-containing perivas-
cular nerves to cerebral arteries than the sympathetic SCG
(Milner et al. 2000b).
Since this denervation study suggests that ET-1-positive
perivascular nerves of large cerebral arteries may be the
projections of primary afferent sensory neurons of the TG
this raises the possibility that ET-1 may co-exist with other
sensory transmitters such as the neuropeptides substance
P and calcitonin gene-related peptide (CGRP), known
to be present in TG sensory nerves projecting to large
Fig. 5 Perivascular nerve/axon varicosities in basilar artery of a
normal (A) and hypertensive (B) rats immunolabelled for ET-1. a Note
granular (gv) and agranular (av) vesicles; core of granular vesicles is
intensely labelled for ET-1. In B note damaged axon varicosity with
clustered agranular vesicles (av), vacuoles with dense material (v), and
‘empty’ areas of axoplasm (asterisk). Adjacent ET-1-negative varicos-
ity (Ax) is of normal appearance with evenly distributed vesicles.
Bars: 0.2 µm. Rabbit polyclonal ET-1 antibodies to human/porcine
ET-1 (a from CRB, Cambridge, UK; b from Sigma, Poole, UK) was
used at 1:1,000 in the preembedding PAP method; antibodies do not
cross-react with big ET but may with ET-2 and ET-3. A is modified
from Loesch et al. Neuroreport 1998, 9:3903-3906 [Lippincott
Williams & Wilkins] and B is from Milner et al. J Vasc Res 2000;
37:39-49 [S Karger AG, Basel/Medical and Science publishers],
which is kindly acknowledged
Fig. 6 Capybara basilar artery perivascular nerves labelled (black
precipitate) for ETA (A) and ETB (B) receptors. In a and b note axons
(Ax) and Schwann cell profiles (Sch) displaying immunoreactivity
(arrows) for ETA and ETB receptors, respectively; some labelling is
seen in the granular vesicles. In C note ETB localisation in the
Schwann cells only, while associated axon varicosities is negative for
ETB receptors. Bars: 0.5 µm. Rabbit polyclonal antibodies ETA and
ETB (Alomone Labs, Jerusalem, Israel) were used at 1:400 in pre-
embedding ExtrAvidin method. The ETA receptor antibody (AER-
001) recognises intracellular (C-terminus) epitope corresponding to
amino acid residues 413-426 of rat ETA peptide (Accession P26684),
while the ETB receptor antibody (AER-002) recognises intracellular
(i3 loop) epitope corresponding to residues 298-314 of rat ETB peptide
(Accession P21451). Both antibodies were affinity purified on
immobilized antigens. (A-C are modified from Loesch et al., J Mol
Histol 2005; 36: 25-34 [Kluwer and Springer Science and Business
Media], which is kindly acknowledged)
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immunocytochemical study in capybara, the largest rodent,
revealed that cerebrovascular nerves contain both ETA and
ETB receptors (Fig. 6), suggesting that neurotransmission
involving ET-1 occurs in cerebral arteries (Loesch et al.
2005). Patients with cerebrovascular disease exhibit an
increased expression of ETB receptors (Hansen-Schwartz
2004; Hansen-Schwartz et al. 2002) and the expression of
ETB receptors has also been described in perivascular
nerves of microvessels of the sensorimotor cortex and
hippocampus after brain trauma (Kallakuri et al. 2007)
where it is suggested that ETB receptor expression is linked
with both vasoconstriction and attenuation of ET-1 synthe-
sis and availability.
A number of studies describe in detail a variety of
pharmacological and physiological effects linked with ET-1
and the adventitial region of cerebral vessels. These include
experiments with the injections of ET-1 to the cisterna and
vertebral artery (Mima et al. 1989) as well as using well-
established cerebral artery occlusion models, mostly of the
middle cerebral artery in the rat or mouse simulating stroke
and ischemic conditions in adjacent brain tissue (Ahn et al.
2002; Callaway et al. 2003; Gresle et al. 2006; Gupta et al.
2006; Miller et al. 2006). In these models, localised
microinjection of ET-1 affects the perivascular but not the
lumenal compartment of the middle cerebral artery causing
vasoconstriction. ET-1 was proposed as a major cause of
cerebral vasospasm in subarachnoid hemorrhage (SAH),
and having stronger vasoconstrictor effects than ET-2 and
ET-3 (Zimmermann and Seifert 1998). This phenomenon
(and/or similar ones) may also shed some light on the
possible involvement of ET-1-containing cerebrovascular
nerves in vasoconstriction where stimulation of such nerves
releases neural ET-1 resulting in vasoconstriction of the
cerebral artery that they innervate. This hypothesis might
also be extended to other vascular beds including the rat
femoral artery, where sustained arterial constriction follow-
ing prolonged exposure to perivascular ET-1 was reported
(Ahn et al. 2002).
In addition to adventitial cerebrovascular nerves the
adventitial Schwann cells of the vessel wall are also
implicated in certain mechanisms related to the action of
ET-1. For example, in the adventitia of the middle cerebral
artery of man a close apposition of ET-1-positive Schwann
cells and ET-1 negative axon varicosities have been
observed suggesting an interaction between these cells
(Loesch et al. 2004). There is a suggestion that glial cells,
such as astrocytes, are the main local source of ET-1 in the
subarachnoid space following hemorrhage and cerebral
ischemia (Pluta et al. 1997). Therefore, the possibility
exists that ET-1 derived from glial cells, rather than from
the cerebral vascular endothelium, is the likely participant
Fig. 7 Endothelin and its receptors on human sural nerve. a Location
of human sural nerve: (From Aktan Ikiz et al. 2005) sn:sural nerve, lm:
lateral malleolus, idcn: intermediate dorsal cutaneous nerve. b Distribu-
tion of ET-1, ETA and ETB receptors on human sural nerve sections
revealed by in vitro autoradiography using radiation-sensitive film (low
resolution). c Microscopic localisation of ET-1 on a section of human
sural nerve. Left panel is a dark-field illumination, ‘high resolution’
autoradiograph of a section incubated in
125I-labelled ET-1 and detected
using nuclear emulsion where white grains show receptor binding sites.
Right panel is the haemotoxylin and eosin stained tissue. There is strong
binding to the epineurial vessels (BVS), perineurium (arrowheads)a n d
vasa nervorum (small cell clusters within the nerve fascicles surrounded
by the perineurium). Scale bars=2 mm for autoradiographs in B and
50 µm for C (B and C modified from Dashwood and Thomas 1997)
58 M.R. Dashwood, A. Loeschin certain cerebrovascular disorders (Pluta et al. 1997). It is
also recognised that ET-1 plays a role in Schwann cells
during nerve development and degeneration and that ET-1
can stimulate or inhibit the release of neurotransmitter(s)
from sympathetic neurons (Damon 1999; Barti-Mattera et
al. 2001; Pomonis et al. 2001). Taken together the data
regarding ET-1-positive perivascular nerves, ET-1-positive
Schwann cells, and the location of ETA and/or ETB
receptors on these cells should not be overlooked, in
particular in regard to the vasomotor control of cerebral
vessels. It is likely that these perivascular nerves and
Schwann cells are potential sources of neural ET-1 in the
vessel wall, where they play a role perhaps as important as
that of endothelium-derived ET-1.
Neurovascular actions of ET-1 in peripheral nerve
While identifying neural ET-1-containing sites histological-
ly, such studies generally fail to provide supporting
evidence of function (Loesch 2005; Tsui and Dashwood
2005). Concluding that ET-1-mediated effects are ‘neuro-
nal’, based purely on the visualisation of the peptide in
nerve tissue overlooks the potential that such effects may be
vascular in origin. Reduced blood supply to nerve and
subsequent ischaemia may have a pronounced effect on
nerve function. Thus, certain neurotransmitter actions may
be secondary to ET-1-induced constriction of the endoneu-
ral vessels and vasa nervorum. For example, local applica-
tion of ET-1 to rat sciatic nerve causes reduced axonal
conduction, due to a localised effect on epineurial micro-
vessels and subsequent ischaemia of the nerve (Cameron et
al. 1994). A later report, using a diabetic rat model, showed
that endogenous ET-1 plays a potential role in diabetic
neuropathy via an action on nerve blood perfusion (Stevens
and Tomlinson 1995). Here, using streptozotocin-induced
diabetic rats, after 6 weeks of untreated diabetes, infusion
of an ETA receptor antagonist caused a significant increase
in sciatic nerve conduction whereas in non-diabetic rats it
was ineffective. In diabetic rats sciatic nutritive endoneurial
blood flow was reduced, an effect that was significantly
ameliorated by ETA receptor antagonist treatment. In non-
diabetic rats antagonist treatment had no effect on blood
flow, suggesting that ET-1 is not involved in the control of
nerve blood flow in normal rats but makes a major
contribution to the perfusion deficit in experimental
diabetes raising the possibility that ET-1 receptor blockade
may have therapeutic potential in diabetic patients (Stevens
and Tomlinson 1995).These observations may be relevant
to data obtained in human sural nerve biopsies where, using
in vitro receptor autoradiography, [
125I]-ET-1 binding was
associated with various structures, in particular the peri-
neurium, endoneurial vessels and vasa nervorum (Fig. 7;
Dashwood and Thomas 1997). This binding was reduced
(competitively) when sural nerve sections were incubated in
the presence of the mixed ET receptor antagonist, bosentan,
providing evidence that (like the diabetic rat model) the
‘neuropeptide’ role of ET-1 may be mediated via ‘neuro-
vascular’ effects where altered nerve conduction is associ-
ated with an ET-1-induced reduction in nerve blood flow
and subsequent nerve ischaemia (Dashwood and Thomas
1997).
Conclusions
Apart from the well-established vasoactive and proliferative
effects of the endothelins, in particular ET-1, it is suggested
that this peptide also possesses neurotransmitter activity.
While a neuropeptide role for ET-1 is supported by its
histological identification in both the central and peripheral
nervous systems caution is needed in interpretation of
results since certain ‘neural’ effects of this peptide may be
due to its potent neurovascular action. However, the
therapeutic potential of endothelin receptor subtype-
selective antagonists in a number of neural conditions
remains regardless of their site of action.
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